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Abstract The mitochondrial 12S rRNA has been shown to be the hot spot for mutations associated with both
aminoglycoside-induced and non-syndromic hearing loss. Of all the mutations, the homoplasmic A1555G and
C1494T mutations at a highly conserved decoding region in the 12S rRNA have been associated with aminoglyco-
side-induced and non-syndromic hearing loss in many families worldwide. The A1555G or C1494T mutation is ex-
pected to form novel 1494C-G1555 or 1494U-A1555 base-pair at the highly conserved A-site of 12S rRNA. These
transitions make the secondary structure of this RNA more closely resemble the corresponding region of bacterial
16S rRNA. Thus, the new UA or G-C pair in 12S rRNA created by the C1494T or A1555G transition facilitates the
binding of aminoglycosides, thereby accounting for the fact that the exposure to aminoglycosides can induce or
worsen hearing loss in individuals carrying these mutations. Furthermore, the growth defect and impairment of mi-
tochondrial translation were observed in cell lines carrying the A1555G or C1494T mutation in the presence of
high concentration of aminoglycosides. In addition, nuclear modifier genes and mitochondrial haplotypes modulate
the phenotypic manifestation of the A1555G and C1494T mutations. These observations provide the direct genetic
and biochemical evidences that the A1555G or C1494T mutation is a pathogenic mtDNA mutation associated with
aminoglycoside-induced and nonsyndromic hearing loss. Therefore, these data have been providing valuable infor-
mation and technology to predict which individuals are at risk for ototoxicity, to improve the safety of aminoglyco-
side antibiotic therapy, and eventually to decrease the incidence of deafness.
Hearing loss affects one in every 1, 000 newborns［1，
2］. Hearing loss can be classified as genetic or
non-genetic, prelingual or postlingual, and syndromic
or nonsyndromic. About 50% of hearing loss cases
have a genetic etiology or predisposition with
autosomal dominant, autosomal recessive, X-linked or
maternal patterns of inheritance. These have rapidly
been defined at molecular levels[3-8]. Hearing loss can
result from a mutation in a single gene or from a
combination of mutations in different genes. Hearing
loss can also be caused by environmental factors,
including perinatal infection, acoustic or cerebral
trauma affecting the cochlea or ototoxic drugs such as
aminoglycoside antibiotics［3, 4］. Additionally, deafness
can result from the interaction of hereditary and
environmental factors.
Aminoglycoside antibiotics such as gentamicin,
streptomycin, kanamycin and tobramycin, are
clinically important drugs. These antibiotics are
composed of amino sugars linked to a
2-deoxystreptamine ring (Figure 1, ring II). The
conserved elements among aminoglycosides are rings I
and II, and particularly the amino groups at positions 1
and 3 within ring II. These elements are essential for
binding to the decoding site of 16S ribosomal RNA
(rRNA). The 2-deoxystreptamine ring is substituted
most commonly at positions 4 and 5, as in the
neomycin class, or at positions 4 and 6, as in the
kanamycin and gentamicin class (Figure 1). They are
particularly active against aerobic, gram-negative
bacteria and act synergistically against certain
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gram-positive organisms. In the developed countries,
these drugs are mainly used in the treatment of
hospitalized patients with aerobic gram-negative
bacterial infections, particularly in patients with
chronic infections such as cystic fibrosis or tuberculosis
［9, 10］. However, in developing countries,
aminoglycosides are more routinely used, even for
relative minor infections. These drugs are highly polar
cations, which are not easy to be metabolized［11］.
Glomerular filtration rapidly clears
aminoglycosides from the majority of tissues and
organs ［11, 12］. However, these drugs may become
concentrated in renal tubular cells, and the perilymph
and endolymph of the inner ear［13, 14］. The use of these
drugs can frequently lead to toxicity, which involves
the renal, auditory and vestibular systems［9, 10, 15］. The
renal impairment is usually reversible, but the auditory
and vestibular ototoxicity is usually irreversible.
Although all of aminoglycosides are capable of
affecting cochlear and vestibular functions,
some(streptomycin and gentamicin) produce
predominately vestibular damage, while others
(neomycin and kanamycin) cause mainly cochlear
damage. Tobramycin affects both equally［10］.
Nearly four million courses of aminoglycosides
are administrated annually in the United States［16］ and
it is estimated that at least 2-5% of patients treated
with these antibiotics develop clinically significant
hearing loss［71-19］. The problem of ototoxic side effects
is more acute in developing countries, where highly
effective and low cost drugs such as aminoglycosides
are often prescribed without adequate monitoring. The
use of these antibiotics has been widespread in China
and the administration of various aminoglycosides was
believed to be responsible for 22% of all deaf-mutes in
one Shanghai district alone ［20］. Of these, 28% had
relatives with aminoglycoside ototoxicity［20］. Recently,
we showed that 48% of 128 Chinese pediatric deaf
subjects could be the result of aminoglycoside
treatment［21］. The type and doses of aminoglycoside
medication, the length of treatment, and age of drug
administration also contribute to the severity of hearing
impairments in some subjects. At the highest doses of
the drugs, most individuals exhibit toxicity. By
contrast, some patients developed
aminoglycoside-induced hearing loss after treatment
with conventional doses - even a single dose - over a
short period. These cases of aminoglycoside
ototoxicity may have a genetic etiology or
predisposition with autosomal dominant, autosomal
recessive, X-linked or mitochondrial patterns of
inheritance. In particular, susceptibility to
aminoglycoside-induced hearing loss is maternally
inherited in humans in a significant proportion of
cases［22-24］. Hu et al. described 36 Chinese families
with maternally transmitted predisposition to
aminoglycoside ototoxicity［20］, while Higashi reported
that 26 of 28 Japanese families with
streptomycin-induced deafness had maternally
inherited transmission［25］.
These drugs are known to exert their antibacterial
effects by directly binding to 16S rRNA in the 30S sub-
unit of the bacterial ribosome, causing mistranslation
or premature termination of protein synthesis［26-27］. In
particular, the aminoacyl-tRNA-binding site (A-site) of
small rRNA has been shown to be the primary target
site for aminoglycoside antibiotics［28-30］. As the mito-
chondria are evolved from bacteria, mitochondrial ribo-
Figure.1 Antibiotics that interfere with the decoding process and with ribozyme catalysis. (A) Neomycin-class antibiotics with a
2-deoxystreptamine (ring II), distributed at positions 4(ring I) and 5(rings III and IV). (B) Kanamycin-class antibiotics and (C)
Gentamicin C1A with substitutions at positions 4 (ring I) and 6 (ring III).
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somes share more similarities to bacterial ribosomes
than do cytosolic ribosomes ［23, 31］. Therefore, it is sug-
gested that one of the primary targeting sites for the
aminoglycoside antibiotics is the small ribosomal RNA
of mitochondrial ribosome［23］. In fact, in familial cases
of otoxic deafness, the aminoglycoside hypersensitivi-
ty is often maternally transmitted, suggesting that muta-
tion(s) in mitochondrial DNA (mtDNA), particularly in
12S rRNA gene, could be the molecular basis for this
susceptibility［22, 23］. Thus, it has been proposed that the
exposure to aminoglycosides leads to an impairment of
mitochondrial translation in susceptible subjects by in-
teracting with the binding sites of mitochondrial 12S
rRNA［24, 31, 32］.
Identification of mitochondrial 12S rRNA mutations
associated with aminoglycoside ototoxicity.
Prezant et al. first investigated the molecular basis
of this disorder by mutational analyses of the mitochon-
drial genome of three Chinese families with maternally
transmitted aminoglycoside ototoxicity and a large Ar-
ab-Israeli family with maternally inherited nonsyn-
dromic deafness［32］. As a result, the A-to-G transition
at position 1555(A1555G) in the 12S rRNA gene was
identified in matrilineal relatives of all three Chinese
families and the Arab-Israeli family but not in 278 con-
trol subjects［32］. The A1555G mutation is located at the
A-site of the small ribosomal subunit, which is highly
conserved from bacteria to mammals［33-34］. The homolo-
gous region of 16S rRNA in Escherichia coli is an es-
sential part of the decoding site of the ribosome［34, 35］
and is crucial for subunit association either by
RNA-protein or RNA-RNA interaction［36］. This region
is also an important locus of action for aminoglycosides
［37, 38］. In particular, the wild type E. coli exhibits sensi-
tivity to aminoglycosides, because drugs including par-
omomycin, neomycin interact with the C1409-G1491
base-pairing of A-site of bacterial 16S rRNA［37, 38］. Mu-
tations, which disrupted the 1409-1491 base pair of E.
coli 16S rRNA or Saccharomyces cerevisiae mitochon-
drial 15S rRNA or Tetrahymena thermophila17SrRNA,
confer aminoglycoside resistance［39-43］. In humans, the
nucleotide at position 1555 in the mitochondrial 12S
rRNA(equivalent to position 1491 in the E. coli 16S
rRNA) in wild-type cells is A, which, when mutated to
a G, as in the Arab-Israeli family, paired with the C at
position 1494(Figure 2). This transition makes the sec-
ondary structure of this rRNA more closely resemble
the corresponding region of E. coli 16S rRNA (Figure
2). Thus, this new G-C pair in 12S rRNA is also expect-
ed to create a binding site for aminoglycosides, which
facilitates the binding of these drugs［44］.
Subsequently, the A1555G mutation has been
found in many families worldwide, such as Asian,
Caucasian or African［21, 31, 45-60］. Aminoglycoside-induced
deafness associated with the A1555G mutation has also
been reported in many sporadic individuals［21, 31, 47, 55］.
This mutation is often present in homoplasmic form in
the affected or at-risk individuals, while matrilineal
relatives of eight Spanish families carry the
heteroplasmic form［28, 59］. The dosage and the age at the
time of aminoglycoside administration seem to be
associated with the severity of hearing loss in some
individuals carrying the A1555G mutation. In
particular, we showed that nine matrilineal relatives
with aminoglycoside ototoxicity in a Chinese family
exhibited varying severity and audiometric
configuration of hearing impairment, although these
subjects share some common features: bilateral and
sensorineural hearing impairment［60］. This discrepancy
likely reflects the dosage and the age at the time of
aminoglycoside administration, and different nuclear
backgrounds in those individuals.
In the absence of exposure to aminoglycosides,
the A1555G mutation also produces a nonsyndromic
hearing loss in many families. However, symptoms of
progressive matrilineal hearing loss, premature
graying, depigmented patches, and digital anomalies in
a large Filipino-American family were also associated
with the A1555G mutation in the 12S rRNA gene in
both affected and unaffected maternal relatives ［54］,
while maternally inherited cardiomyopathy and
hearing loss was associated with the A1555G mutation
［61］. Matrilineal relatives of intra-families or
inter-families carrying the A1555G mutation exhibited
variable penetrance and expressivity including severity
and age-of-onset in hearing impairment, ranging from
profound congenital deafness, to severe and moderate
progressive hearing loss of later onset, to completely
normal hearing［32, 48, 53］. These data indicate that the
A1555G mutation is a primary factor underlying the
development of deafness and that other modifier
factors play a role in the phenotypic expression of the
hearing loss associated with the A1555G mutation［62-67］.
To identify additional mutations causing drug
susceptibility in the 12S rRNA gene, a systematic and
extended mutation screening of the mitochondrial 12S
rRNA gene has been initiated in two hearing-impaired
Chinese populations［21, 55, 68］. As a result, a homoplasmic
C-to-T transition at position 1494(C1494T) in the 12S
rRNA gene has been identified in a large Chinese
family with maternally transmitted
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aminoglycoside-induced and non-syndromic
deafness［68］. In the absence of aminoglycosides, some
matrilineal relatives in this family exhibited late-onset/
progressive deafness, with a wide range of severity and
age at onset. Notably, the average age of the onset of
deafness has changed from fifty-five years(generation
II) to ten(generation IV). Clinical data show that the
administration of aminoglycosides can induce or
worsen deafness in matrilineal relatives. The age at the
time of drug administration appears to be correlated
with the severity of hearing loss experienced by
affected individuals. As shown in Figure 2, the C1494T
mutation is expected to form a novel U1494-1555A
base pair, which is in the same position as the
C1494-1555G pair created by the deafness-associated
A1555G mutation, at the highly conserved A site of
12S rRNA［68］. This alteration in the tertiary structure of
12S rRNA is also expected to create a binding site for
aminoglycosides, thereby causing the sensitivity to
these drugs［32, 44, 68］.
Furthermore, sequence analysis of the complete mi-
tochondrial genomes in four Chinese subjects with ami-
noglycoside induced and nonsyndromic hearing impair-
ment identified homoplasmic T1095C mutation in 12S
rRNA［21, 69］. This mutation was absent in 364 Chinese
controls［68］. This mutation was identified in an Italian
Figure 2. The site of A1555G and C1494T mutations in the decoding region of mitochondrial 12S
rRNA. The A-site of E. coli 16S rRNA oligonucleotide showing the dimethyl sulfate (DMS) footprints,
observed in the presence of aminoglycosides neomycin or paromomycin, is marked with a dot (A) (28,
29). The corresponding region of S. cerevisiae mitochondrial 15S rRNA and human mitochondrial 12S
rRNA is shown as the wild-type version (B, D) and in the version carrying the C14049G (nt 1477 in S.
cerevisiae 15S rRNA) (C), human mitochondrial 12S rRNA A1555G (E) and C1494T (F) mutations,
respectively.
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family with auditory neuropathy, aminoglycoside-in-
duced hearing loss and Parkinsonism［70］, another Italian
family with maternally inherited hearing loss ［71］ and a
Chinese subject with auditory neuropathy［64］. In fact,
the occurrence of the T1095C mutation in these geneti-
cally unrelated subjects affected by hearing impairment
strongly indicates that this mutation is involved in the
pathogenesis of hearing impairment, including amino-
glycoside ototoxicity. This T-to-C transition disrupted
an evolutionarily conserved base-pair at stem loop of
the helix 25 of 12S rRNA［34］. This nucleotide is also lo-
cated at the P-site of ribosome, suggesting an impor-
tant role in the initiation of mitochondrial protein syn-
thesis［70］. The alteration of the tertiary or quaternary
structure of this rRNA by the T1095C mutation may
lead to impairing mitochondrial protein synthesis,
thereby causing the mitochondrial dysfunction associat-
ed with hearing impairment.
The mutations at position 961 occur in genetically
unrelated families and sporadic subjects affected by
aminoglycoside-induced and nonsyndromic hearing
loss. These include ET961Cn mutation in Caucasian
and Asian subjects［73-75］, 961-Cinsertion in Caucasian
and Asian subjects［21, 53, 68, 75, 76］, T961G mutation in Cau-
casian subjects［77］ and T961C mutation in Chinese sub-
jects［21］. These observations imply that this mutation is
involved in the pathogenesis of this disorder. The 961
mutation localizes at the C-cluster of the region be-
tween loop 21 and 22 of 12S rRNA［34］. This region is
not very evolutionarily conserved and its function is
not well defined, specifically for its interaction with
aminoglycosides in bacterial homologues. It is possi-
ble that the alteration of the tertiary or quaternary struc-
ture of this rRNA by the 961 mutation may indirectly
affect the binding of aminoglycosides. Alternatively,
this alternation may result in a mitochondrially transla-
tional defect.
Molecular pathogenesis of mitochondrial 12S rRNA
mutations associated with aminoglycoside ototoxicity.
The A1555G and C1494T mutations, as shown in
Figure 2, created a highly conserved 1494-1555 G-C or
A-U base-pairing at the A site of mitochondrial ribo-
some where the codon-anticodon recognition
occurs［28, 29, 34］. This corresponding base-pair of E. coli
16S rRNA is adjacent to the A-site tRNA-binding bas-
es including A1408, A1492 and A1493［27,29, 37］. Thus, the
A1555G or C1494T mutation may result in a local con-
formational change in the A-site of mitochondrial 12S
rRNA, thereby affecting the efficiency and accuracy of
codon-anticodon interaction. As a result, these muta-
tions lead to impairment of mitochondrial translation.
In fact, ~28% and 50% average decrease, despite a con-
siderable variability, in the rate of mitochondrial pro-
tein labeling, were observed in lymphoblastoid cell
lines derived from 9 asymptomatic and 10 symptomat-
ic individuals of the Arab-Israeli family, respectively
［62］. Under a constant nuclear background, ~35% and ~
37% average reduction in the rate of mitochondrial pro-
tein labeling was observed in cybrid cell lines derived
from asymptomatic individuals or from symptomatic
individuals from this family［63］. Similarly, cybrid cell
lines derived from asymptomatic members, and cybrid
cell lines derived from symptomatic members of the
Chinese family carrying the C1494T mutation exhibit-
ed ~38% and 43% decrease in the rate of mitochondri-
al protein labeling, respectively, compared with cy-
brids derived from Chinese control individuals ［78］.
Thus, the A1555G or C1494T mutation indeed produc-
es the primary mitochondrial translational defect with a
decrease of ~30-40% mitochondrial protein synthesis
rate. However, ~50% decrease in the rate of mitochon-
drial protein synthesis responsible for a significant re-
duction in oxygen consumption is likely below the
threshold level to produce the deafness phenotype asso-
ciated with the A1555G or C1494T mutation［62, 78］. The
incomplete penetrance of hearing loss and the mild bio-
chemical defects clearly indicated that the A1555G or
C1494T mutation is the primary factor for the hearing
impairment but itself is not sufficient to produce a clini-
cal phenotype. Therefore, other modifier factors, such
as nuclear modifier genes, mitochondrial haplogroups
and aminoglycosides, modulate the phenotypic mani-
festation of the A1555G or C1494T mutation.
Nuclear modifier genes have been proposed to
modulate the phenotypic manifestation of the A1555G
or C1494T mutation. Extensive genome-wide linkage
studies in Arab-Israeli and Spanish-Italian families re-
vealed that the phenotypic expression of the A1555G
mutation is influenced by a complex inheritance of
multiple nuclear-encoded modifier genes［79］. Despite
the statistical support for the linkages of several puta-
tive modifier loci, including one locus localized to
chromosome 8p23.1［80, 81］, none of mutations in these
modifier genes have been identified. Thus, it is very
difficult to identify such nuclear modifier genes by us-
ing conventional genetic approaches such as ge-
nome-wide linkage analysis. Recently, we have pro-
posed an interesting model for nuclear-mtDNA interac-
tion for the phenotypic manifestation of the A1555G or
C1494T mutation. The mutant alleles of yeast S. cerevi-
siae MTO1 or MSS1 or MTO2, encoding mitochondrial
proteins, manifest a respiratory-deficient phenotype on-
·· 69
Journal of Otology 2006 Vol. 1 No. 2
ly when coupled with the paromomycin-resistance mi-
tochondrial 15S rRNA C1409G mutation (PR454 or PR)
corresponding to sites for human deafness-associated
12S rRNA A1491G and C1409T mutations［67, 82, 83］.
These strongly indicate that Mss1p or Mto1p or Mtop2
affects the phenotypic expression of the C1409G muta-
tion by functionally interacting with the region of the
C1409G mutation in the15S rRNA. In E.coli, the prod-
ucts of mnmE (homolog of MSS1)［84］, gidA (homolog of
MTO1)［85］ and trmU［86］have been shown to be involved
in the biosynthesis of the hypermodified nucleoside
5-methyl-aminomethy-2-thio-uridine(mnm5s2U34) ［87］.
This modified nucleotide, found in the wobble position
of several bacterial tRNAs specific for glutamate, ly-
sine, arginine, and glutamine, has a pivotal role in the
structure and function of tRNAs, including structural
stabilization, aminoacylation and codon-recognition at
the decoding site of small ribosomal RNA［85, 87］. Recent-
ly, we demonstrated that isolated human MTO1 or GT⁃
PBP3 (homolog of MSS1) or TRMU (homolog of
MTO2) cDNA can complement the respiratory defi-
cient phenotype of yeast mto1, mss1 or mto2 cells carry-
ing the phenotype of yeast mto1, mss1 or mto2 cells car-
rying the 15S rRNA C1409G mutation, suggesting that
the functions of those proteins are evolutionarily con-
served［66, 67］. Thus, mutations in MTO1, MSS1/GTPBP3
and MTO2/TRMU likely act as a modifier factor leading
to a failure in mitochondrial tRNA metabolism, thereby
worsening defects in mitochondrial protein synthesis in
cells carrying the A1555G or C1494T mutation. Of
these, genotyping analysis of TRMU in 613 subjects of
an Arab-Israeli kindred and 210 Italian/Spanish fami-
lies and 31 Chinese pedigrees carrying the A1555G or
C1494T mutation revealed a missense mutation(G28T)
altering an invariant amino-acid residue(A10S) in the
evolutionarily conserved N-terminal region of Trmu
protein[88]. Interestingly, all eighteen Arab-Israeli or Ital-
ian-Spanish matrilineal relatives carrying both the
TRMU A10S and 12S rRNA A1555G mutations exhibit-
ed congenital profound deafness. Functional analysis
showed that this mutation did not affect importing of
Trmu precursors into mitochondria. However, the ho-
mozygous A10S mutation leads to a marked failure in
mitochondrial tRNA metabolisms, specifically reduc-
ing the steady-state levels of mitochondrial tRNAs. As
a consequence, these defects contribute to the impair-
ment of mitochondrial protein synthesis. Resultant bio-
chemical defects aggravate the mitochondrial dysfunc-
tion associated with the A1555G mutation, exceeding
the threshold for expressing the deafness phenotype.
These findings indicate that the mutated TRMU, acting
as a modifier factor, modulates the phenotypic manifes-
tation of the deafness-associated 12S rRNA mutations.
Furthermore, mtDNA variants/haplotypes have
been implicated to influence the penetrance and expres-
sivity of hearing loss associated with primary muta-
tions. The second LHON-associated mtDNA mutations
at positions 4216 and 13708 were implicated to in-
crease the penetrance of the deafness-associated
A7445G mutation in the precursor of tRNASer(UCN) gene
in the New Zealand family than the Scottish pedigree
［89-93］. The ND1 T3308C and tRNAAla T5655C mutations
likely contribute to the higher penetrance of deafness
in an African pedigree than Japanese and French fami-
lies carrying the tRNASer(UCN) T7511C mutation
［94－ 98］. Furthermore, the G7444A mutation in the COI
gene /precursor of tRNASer(UCN) gene was implicat-
ed to influence the penetrance and expressivity of the
A1555G mutation［99］ and the primary LHON-associat-
ed mtDNA mutations［100］. On the H strand of mtDNA,
this mutation results in a read-through of the stop co-
don AGA of the COI message, thereby adding three
amino acids(Lys-Gln-Lys) to the C-terminal of the
polypeptide. Thus, the mutated polypeptide may retain
a partial function. Alternatively, the G7444A mutation
is adjacent to the site of 3’end endonucleolytic pro-
cessing of L-strand RNA precursor, spanning tRNAS-
er(UCN) and ND6 mRNA［60, 93, 101］. Thus, the G7444A muta-
tion, similar to the A7445G mutation, may also cause a
defect in the processing of the L-strand RNA precursor,
thus causing mitochondrial dysfunctions.
Aminoglycoside is the predominating modifier
factor for hearing loss associated with 12S rRNA
mutations. In fact, the new U-A or G-C pair in 12S
rRNA created by the C1494T or A1555G transition
makes the decoding site of the secondary structure of
this rRNA more closely resemble the corresponding
region of E. coli 16S rRNA ［7, 14, 24］. Thus, these
mutations facilitate the binding of aminoglycosides［36,
60］. These drugs, which are concentrated in the
perilymph and endolymph of the inner ear［5, 6］,
may impair mitochondrial translation in cochlear cells
in susceptible subjects carrying the A1555G or
C1494T mutation. As a consequence, the exposure to
aminoglycosides leads to tissue specific defects in
those cells, thereby inducing or worsening hearing loss
in individuals carrying these mutations. In fact, the
significant defects growth rate in the presence of high
concentration of paromomycin or neomycin were
observed in lymphoblastoid or cybrid cell lines or
derived from either symptomatic or asymptomatic
individuals carrying the A1555G or C1494T mutation,
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as compared with the average rate in control cells［54, 56, 60,
70］. The reduced growth rate of mutant lymphoblastoid
or cybrid cells carrying the A1555G or C1494T
mutation in media containing paromomycin is most
probably due to a worsening of mitochondrial
translation and subsequent respiration defect ［56, 70］.
However, no mutant proteins were detected in
lymphoblastoid or cybrid cells carrying the A1555G
mutation ［37, 38, 56］. Thus, aminoglycosides, acting as
modifier factors, lead to an additional 30% decrease in
the rate of mitochondrial protein synthesis in cells
carrying the A1555G or C1494T mutation, reducing
the overall mitochondrial translation rate down to and
below the minimal level required for normal cell
function, thus inducing the deafness phenotype［64, 78］.
Prevalence of ototoxic mitochondrial 12S rRNA
mutations.
In the familial cases of aminoglycoside ototoxicity,
the susceptible mutations in the 12S rRNA gene
account for a significant portion［21, 32, 49-57, 60, 68, 69］. In the
sporadic populations with aminoglycoside ototoxicity,
the A1555G mutation appears to be more frequently
than other mutations such as A1494T and T1095C
mutations. The incidence of the A1555G mutation
varies in hearing-impaired populations from different
ethnic origins. In certain populations, the A1555G
mutation appears to be more frequent, while in other
populations, this mutation exhibited very low
incidence. The A1555G mutation accounts for 33% of
a Japanese outpatient population with a history of
exposure to aminoglycosides ［102］, while 13% of
Chinese pediatric subjects with aminoglycoside
ototoxicity carry the A1555G mutation ［21］. In two
different cohorts of sporadic Chinese subjects with
aminoglycoside ototoxicity, 5-6% of sporadic patients
carry the A1555G mutation［31, 73, 74］. In two different
Caucasian populations, 17% and 17.7% of cases in the
United States and Spain with aminoglycoside
ototoxicity carry the A1555G mutation, respectively［48,
103］. However, the incidence of A1555G mutation in
nonsyndromic hearing loss is much lower than in those
with aminoglycoside ototoxicity. In other Caucasian
clinical populations with nonsyndromic hearing loss,
the frequency of the A1555G mutation varies: 2.4% in
a Danish cohort ［104］, 1.8% and 0.7% in Hungarian and
Germany populations ［105］, 2.5% in a UK cohort［106］,
1.8% in Turkish pediatric population［82］ and 0.6% in
164 Caucasian American pediatric subjects ［77］.
However, in Asian nonsyndromic hearing-impaired
populations, the incidence of the A1555G mutation
appears to be higher than in Caucasians: 2.9% in
Chinese ［21］, 3% in Japanese ［108］ and 5.3% in
Indonesian［109］.
Potential pathophysiological mechanisms of
maternally transmitted aminoglycoside ototoxicity.
Based on these genetic and biochemical evidences,
we propose the following mechanism for maternally
transmitted aminoglycoside ototoxicity, as shown in
Figure 3. We hypothesize that the site of susceptibility
to aminoglycosides is in the mitochondrial ribosomes,
specifically that carrying these A1555G or C1494T
mutation. Aminoglycosides enter and then accumulate
in the cochlear and vestibular mitochondria. Then,
these drugs worsen defects in mitochondrial protein
synthesis caused by the mitochondrial 12S rRNA
A1555G or C1494T mutation. These mitochondrial
translational defects result in a decline in ATP
production in the cochlear and vestibular cells. At same
time, these defects in oxidative phosphorylation would
increase the production of reactive oxygen species
(ROS), thereby damaging mitochondrial and cellular
proteins, lipids and nuclear acids. The hair cells and
cochlear neurons may be preferentially involved
because they are somehow exquisitely sensitive to
subtle imbalance in cellular redox state or increased
level of free radials. Consequently, the mitochondrial
permeability transition pore opens and activates
apoptosis. This would lead to the dysfunction or death
of cochlear and vestibular cells, thereby producing the
phenotype of hearing impairment.
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